diagnosticpowerofroseintbna-130208214417-phpapp01
TRANSCRIPT
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
1/18
A Randomized Prospective trial of theA Randomized Prospective trial of the
Utility ofUtility ofRapid On-Site EvaluationRapid On-Site Evaluation ofof
Transbronchial Needle AspirateTransbronchial Needle Aspirate
SpecimensSpecimens
J Bronchol Intervent Pulmonol 2011;18:121-127
Lonny Yarmus, D,!""P, #homas $an %er &loot, 'D, (oah Lech)*n, 'D, 'ar+ (a*er,'D, Doulas Dressel, 'D, an% Dav*%
!eller-+oman,'D,!""P
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
2/18
BackgroundBackgroundPrevious studies havePrevious studies havesuggested an increased diagnostik yield forsuggested an increased diagnostik yield forflexible bronchoscopic (FB) transbronchialflexible bronchoscopic (FB) transbronchial
needle aspirate (TBNA) specimens fromneedle aspirate (TBNA) specimens fromlymph nodes hen using rapid on!sitelymph nodes hen using rapid on!siteevaluation ("#$%) by cytophatologyevaluation ("#$%) by cytophatology
!b"ective!b"ective to determine the effect of "#$%to determine the effect of "#$%on the diagnostic poer of TBNA&on the diagnostic poer of TBNA&
#ethods#ethodsThe study is a prospectiveThe study is a prospectiverandomi'ed controlled trial&randomi'ed controlled trial&
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
3/18
FB is the most common modality used toFB is the most common modality used todiagnose lung cancerdiagnose lung cancer
TBNA biopsy is a biopsy technique used duringTBNA biopsy is a biopsy technique used duringbronchoscopy which involves passing abronchoscopy which involves passing acatheter containing a needle through thecatheter containing a needle through thetrachea or bronchial wall into the lymph nodestrachea or bronchial wall into the lymph nodesor masses to obtain samples for Cytopathologicor masses to obtain samples for Cytopathologicassesment.assesment.
Conventional TBNA is a blind procedure in that theConventional TBNA is a blind procedure in that thestructures external to the bronchial wall are notstructures external to the bronchial wall are notdirecly visualied. To addres this concern !direcly visualied. To addres this concern !"#$% of spesimens has been carried out."#$% of spesimens has been carried out.
..
Intro%uct*on
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
4/18
&ith "#$% biopsy material is prepared and&ith "#$% biopsy material is prepared andstained during the bronchoscopystained during the bronchoscopy
'f the cytopathologist determine that the biopsy'f the cytopathologist determine that the biopsywas unuccessful! futher TBNA passed canwas unuccessful! futher TBNA passed canbe made during the same procedure!be made during the same procedure!potentially sparing the patient repeated orpotentially sparing the patient repeated oralternative invasive procedure and theiralternative invasive procedure and theirassociated ris( of complication.associated ris( of complication.
Intro%uct*on
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
5/18
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
6/18
0atients were randomied at the time of0atients were randomied at the time of
bronchoscopy into the "#$% or the no/"#$%bronchoscopy into the "#$% or the no/"#$%groupgroup Before the procedure a sub1ective pretestBefore the procedure a sub1ective pretest
clinical probability of malignancy wasclinical probability of malignancy wasdetermined based on the bronchoscopist2sdetermined based on the bronchoscopist2s
clinical suspicion * 0atient age! tobaccoclinical suspicion * 0atient age! tobaccohistory! medical history! 3 radiographichistory! medical history! 3 radiographicimagingimaging
The location of TBNA! number of needleThe location of TBNA! number of needlepasses sie of needle *,4 gauge or 55 gauge!passes sie of needle *,4 gauge or 55 gauge!duration of procedure!effect of on/siteduration of procedure!effect of on/siteassessment! amount of sedative and topicalassessment! amount of sedative and topicalanasthetic medication used were recordedanasthetic medication used were recordedusing a standardied data collection sheet.using a standardied data collection sheet.
Pat*ent .
metho%s
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
7/18
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
8/18
Total of 9- patients with median age of 9- yearsTotal of 9- patients with median age of 9- years
*range7 65 to -- years old were randomied for*range7 65 to -- years old were randomied for
the study between February 5::; and
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
9/18
ATS NodalStation
R!S$ N!%R!S$
5 1 1
) 15 1.
* 5( 5)
1+ ) (
11 + +
#ass ) 5
AT$=american thoracic society> TBNA7 Transbroncial needle
aspiration
#ale 2: #B( natom*c s*te locat*ons
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
10/18
Table ( #ain Results
/3 (-/3
P
#B( D*anost*c Y*el%456
9 1,0
#B( %*anos*s o lunneolasma 456
1,0
#B( %*anos*s o anyneolasma 456
0,80
#B( a%e
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
11/18
Table ) Procedural 8ata
/3 ((-/3
s*rates>*te =,=7 =,1=
#*me4m*n6 2, 27,
'*%a)olam4m6 =,98 ,0
!entanyl4mc6 107 111
L*%oca*ne 154mL6
22,9 22,8
?*stoloy nee%le41 aue6 456
98 =1
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
12/18
Table - Number of Transbronchial Biopsies Performed
R!S$ N!N%
R!S$
Transbronchial biopsiesperformed
9 1-
No transbronchial biopsiesperformed
5. 10
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
13/18
Both group were followed up for period ofBoth group were followed up for period of
up to 5 years after the initial bronchoscopyup to 5 years after the initial bronchoscopy
was performedwas performed
There are no significant statisticalThere are no significant statistical
differences in final TBNA diagnosis! finaldifferences in final TBNA diagnosis! final
tissue diagnosis! and typed of neoplasmatissue diagnosis! and typed of neoplasma
or benign disease diagnosed between theor benign disease diagnosed between the
5 group5 group
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
14/18
Tabel . final diagnosis
:inal
8iagnosis
R!
S$
TB
NA
!ther 8iagnostic
Testing
N!
N%
R!
S$
!ther 8iagnostic
Testing
NS363 11 - &T5, B1, BB1,
TT1'
15 ) &BB1, ;('
S363 ( 1 &$1' ) +
Sarcoid ( ( &T1,#5' 5 ) &T1, #('
#elanoma 1 + + +
6ymphoma 1 + + +
A:B + 1&;1' + +
True
Negative
% . , ;5, 35' % 9 ,3.'
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
15/18
?'$C@$$'#N?'$C@$$'#N
TBNA has become very valuable for theTBNA has become very valuable for the
diagnosis and staging of mediastinal use. Fromdiagnosis and staging of mediastinal use. From"#$% during bronchoscopy has previously"#$% during bronchoscopy has previouslybeen reported to result in improved diagnosticbeen reported to result in improved diagnosticresults for TBNA.results for TBNA.
'n a randomied controlled trial comparing'n a randomied controlled trial comparingprospective "#$% without on/site assessmentprospective "#$% without on/site assessmentof Cytopathology *no/"#$%! we found noof Cytopathology *no/"#$%! we found nobenefit on the adequacy of the diagnostic resultsbenefit on the adequacy of the diagnostic resultsor related to use of the "#$% specimensor related to use of the "#$% specimens
owever! there are chances of decresingowever! there are chances of decresingnumber of transbronchial biopsy is needed innumber of transbronchial biopsy is needed inthe group "#$%.the group "#$%.
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
16/18
?'$C@$$'#N?'$C@$$'#N
'n this study! the use of "#$% was not'n this study! the use of "#$% was not
associated with an improved diagnosticassociated with an improved diagnosticyield or specimen adequacy! reduced oryield or specimen adequacy! reduced orincreased procedure time! or withincreased procedure time! or withamount of sedation topical anasthesiaamount of sedation topical anasthesiarequired and there no difference inrequired and there no difference inmalignancy rates between the "#$%malignancy rates between the "#$%and no/"#$% procedure. 'ts suggestingand no/"#$% procedure. 'ts suggestingthan randomiation may havethan randomiation may haveprevented a preferential use of "#$% inprevented a preferential use of "#$% in
patients with malignant versus benignpatients with malignant versus benignlymadenopathylymadenopathy
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
17/18
ConclusionConclusion
The "#$% procedure should beThe "#$% procedure should be
used on a case by case basis.used on a case by case basis.
arger studies investigating thearger studies investigating the
utility of "#$% on %B@$/TBNA andutility of "#$% on %B@$/TBNA andthe incremental yield of %B@$/the incremental yield of %B@$/
TBNA over standard TBNA whenTBNA over standard TBNA when
performed by experienced providersperformed by experienced providers
are neededare needed
-
8/9/2019 diagnosticpowerofroseintbna-130208214417-phpapp01
18/18
THANKTHANK
YOUYOU